etidronate has been researched along with furosemide in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Charles, P; Hasling, C; Mosekilde, L | 1 |
| Güliter, S; Keleş, H; Keleş, I; Ozkurt, ZN | 1 |
| Nammalwar, BR; Prahlad, N; Shanmughasundharam, R; Vijayakumar, M | 1 |
1 review(s) available for etidronate and furosemide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for etidronate and furosemide
| Article | Year |
|---|---|
Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Topics: Adult; Aged; Calcium; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Female; Furosemide; Humans; Hypercalcemia; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1986 |
6 other study(ies) available for etidronate and furosemide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Risedronate-induced intravascular haemolysis complicated by acute tubular necrosis.
Topics: Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Furosemide; Hemolysis; Humans; Isotonic Solutions; Kidney Tubular Necrosis, Acute; Middle Aged; Risedronic Acid; Sodium Chloride; Treatment Outcome | 2005 |
Subcutaneous fat necrosis with hypercalcemia.
Topics: Administration, Oral; Bone Density Conservation Agents; Calcium; Diuretics; Etidronic Acid; Fat Necrosis; Furosemide; Glucocorticoids; Humans; Hypercalcemia; Infant, Newborn; Infusions, Intravenous; Nephrocalcinosis; Potassium Citrate; Prednisolone; Sodium Chloride | 2006 |